Giancarlo Scaccia

Giancarlo Scaccia is a shareholder in Greenberg Traurig's Intellectual Property Practice, focusing primarily on pharmaceutical patent litigation, including Abbreviated New Drug Application (ANDA) and Hatch-Waxman matters. He also possesses wide-ranging litigation and trial experience across diverse industries. His practice extends to representing clients in post-grant proceedings and due diligence investigations.

His litigation experience appears to lean towards the defense, with one tracked appearance noted on the defendant side and none for plaintiffs. While his firm profile indicates representing "clients" broadly, his specialized focus on ANDA/Hatch-Waxman cases often involves defending generic drug manufacturers.

Scaccia is currently with Greenberg Traurig, where he was elevated to shareholder. He has been recognized in The Best Lawyers in America's "Ones to Watch" for Litigation - Patent and Intellectual Property Law, and as a "Rising Star" by Super Lawyers Magazine in the New York Metro area. While the provided case list includes one untitled defendant-side appearance, specific notable case outcomes or significant trial results are not publicly detailed or tied to named cases in the available web sources. He does, however, represent clients in post-grant proceedings, indicating experience with PTAB/IPR matters.

Giancarlo Scaccia earned his J.D., cum laude, from Benjamin N. Cardozo School of Law in 2015, where he was an Executive Editor of the Cardozo Public Law, Policy and Ethics Journal. He holds a B.A., cum laude, in Biochemistry and Mathematics (minor) from New York University, awarded in 2010. He is admitted to practice in New York and New Jersey.